SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Jensen-Pergakes, Kristen, Tatlock, John, Maegley, Karen A, McAlpine, Indrawan J, McTigue, Michele, Xie, Tao, Dillon, Christopher P, Wang, Yuli, Yamazaki, Shinji, Spiegel, Noah, Shi, Manli, Nemeth, Amy, Miller, Natalie, Hendrickson, Eleanore, Lam, Hieu, Sherrill, John, Chung, Chi-Yeh, McMillan, Elizabeth A, Bryant, Shannon Karlicek, Palde, Prakash, Braganza, John, Brooun, Alexei, Deng, Ya-Li, Goshtasbi, Vesta, Kephart, Susan E, Kumpf, Robert A, Liu, Wei, Patman, Ryan L, Rui, Eugene, Scales, Stephanie, Tran-Dube, Michelle, Wang, Fen, Wythes, Martin, Paul, Thomas A
Published in Molecular cancer therapeutics (01.01.2022)
Published in Molecular cancer therapeutics (01.01.2022)
Get full text
Journal Article